CJC-1295 and Ipamorelin Stack: The Ultimate Combo Guide for Growth Hormone Optimization

If you've spent any time researching peptide therapy, you've almost certainly encountered the CJC-1295/Ipamorelin combination. It's consistently ranked as the most popular peptide stack in clinical and self-directed optimization circles, and for good reason: the two peptides work through distinct but complementary mechanisms that together produce a substantially larger and cleaner growth hormone pulse than either compound alone.

This guide breaks down the science behind the synergy, optimal dosing, timing protocols, cycling strategies, and what you can realistically expect.

Why This Combination Dominates the Peptide Space

CJC-1295 and Ipamorelin both stimulate growth hormone (GH) release, but they do so via entirely different receptor systems. This is the cornerstone of the stack's appeal.

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). GHRH is the upstream signal that tells the pituitary to synthesize and release GH. The modified DAC (Drug Affinity Complex) version of CJC-1295 binds to albumin in the bloodstream, dramatically extending its half-life from minutes to approximately 6–8 days. The non-DAC version (also called Modified GRF 1-29) has a shorter half-life of about 30 minutes and is often preferred for pulsatile dosing.

Ipamorelin is a GH secretagogue and ghrelin receptor agonist (GHSR agonist). It mimics the signal that amplifies GH release at the pituitary level. Critically, Ipamorelin is highly selective — it stimulates GH without significantly raising cortisol or prolactin, which are common side effects of older secretagogues like GHRP-2 and GHRP-6.

The Synergy Explained

The combination works through a mechanism known as synergistic amplification. GHRH (mimicked by CJC-1295) increases the amplitude of GH pulses, while ghrelin agonists like Ipamorelin increase both amplitude and pulse sensitivity. When both pathways are activated simultaneously, the resulting GH pulse is significantly larger than additive — research in animal models and human subjects suggests the combined pulse can be 3–5x greater than either peptide alone.

Think of it this way: CJC-1295 loads the cannon, and Ipamorelin fires it. Using both at the same time maximizes the shot.

Additionally, the two peptides complement each other's safety profiles. CJC-1295 alone produces a broad, sustained GH elevation — useful for baseline optimization but less effective for acute pulses. Ipamorelin alone is safer but produces smaller pulses. Together, they achieve physiological-range GH spikes that mirror natural pulsatile release.

Benefits of the Stack

Research and clinical reports point to several overlapping and additive benefits:

• Body composition: Reduced fat mass, particularly visceral and subcutaneous fat, with preservation or improvement of lean muscle mass
• Recovery acceleration: Faster repair of soft tissue, tendons, and muscle after training
• Sleep quality: GH is predominantly secreted during deep slow-wave sleep; enhancing this pulse typically improves sleep depth and recovery
• Skin and collagen: Increased GH → IGF-1 upregulation → improved collagen synthesis and skin elasticity
• Energy and cognitive clarity: Many users report improved drive and mental sharpness, likely secondary to better sleep and metabolic efficiency
• Bone density: Over longer protocols, IGF-1 elevation supports bone remodeling

Dosing Protocols

Standard clinical and research dosing for the combination:

Standard Protocol

• CJC-1295 (no DAC / Mod GRF 1-29): 100–200 mcg per injection
• Ipamorelin: 100–300 mcg per injection
• Frequency: 1–3 times daily
• Injection type: Subcutaneous, typically abdominal

Many practitioners use a pre-mixed vial at a 1:1 or 1:2 ratio (CJC:Ipamorelin). Pre-mixed blends are commonly offered in 5 mg total doses.

Dosing Timing

Timing matters more with this stack than many others because you're trying to optimize GH pulse timing relative to sleep and fasting state:

• Before bed (most important dose): Inject 30–60 minutes before sleep. GH naturally peaks in the first 90 minutes of deep sleep. Amplifying this pulse with the stack maximizes anabolic and repair effects.
• Morning (fasted): Second-most-effective time. GH pulses occur in the early morning fasted state; adding the stack here extends this natural window.
• Post-workout: A third dose post-exercise can leverage the training-induced GH surge.

Critical rule: Always inject in a fasted state — at least 2–3 hours after the last meal. Elevated insulin blunts GH release and negates much of the stack's effect.

Cycling Protocols

Beginner Cycle

• Duration: 12 weeks on, 4 weeks off
• Dosing: Once daily (before bed)
• Dose: CJC-1295 100 mcg + Ipamorelin 100 mcg

Intermediate/Maintenance Cycle

• Duration: 16–20 weeks on, 6–8 weeks off
• Dosing: Twice daily (morning fasted + before bed)
• Dose: CJC-1295 200 mcg + Ipamorelin 200 mcg per injection

Long-Term Protocol

Some clinicians use continuous low-dose protocols (5 days on, 2 days off) year-round. This mirrors what many HRT-focused physicians prescribe for anti-aging and body composition maintenance. Continuous use requires monitoring of IGF-1 levels every 3–6 months to avoid supraphysiological levels.

Side Effects and Safety

The CJC-1295/Ipamorelin stack is considered one of the safer GH-stimulating options, but it's not without potential effects:

• Water retention: Mild fluid retention is common in the first 2–4 weeks as GH increases aldosterone-related fluid balance. Usually self-resolves.
• Tingling/numbness: Carpal tunnel-like symptoms from transient fluid shifts. Reduce dose if persistent.
• Hunger increase: Ipamorelin mildly stimulates appetite via ghrelin pathways — less than GHRP-6 but still present.
• Injection site reactions: Redness or minor swelling, typically mild.
• IGF-1 elevation: Chronically elevated IGF-1 is theoretically associated with increased cancer risk. This is not demonstrated at peptide doses but warrants monitoring.

Comparing to Other GH Stacks

The CJC-1295/Ipamorelin stack is often compared to CJC-1295 + GHRP-2 or CJC-1295 + GHRP-6. The key difference is selectivity:

• GHRP-2 produces strong GH pulses but also elevates cortisol and prolactin meaningfully
• GHRP-6 causes pronounced hunger and significant cortisol elevation
• Ipamorelin is highly GH-selective with minimal off-target effects

For most users — particularly those prioritizing clean GH optimization without hormonal disruption — Ipamorelin is the superior choice.

You can learn more about Ipamorelin specifically in the Ipamorelin peptide guide and CJC-1295's pharmacology in the CJC-1295 peptide guide. For broader context on GH peptides, see the growth hormone peptides guide.

What to Expect on the Stack

Weeks 1–3

Minimal visible changes. Water retention may be noticeable. Sleep quality often improves noticeably in the first week — this is frequently the first sign the stack is working.

Weeks 4–8

Body composition changes become apparent: midsection tightening, improved muscle fullness, and recovery between training sessions accelerates. Skin improvements are sometimes noted.

Weeks 9–16

Lean mass improvements solidify. Many users report IGF-1 values rising 30–70% from baseline by the end of a 12-week cycle, consistent with clinical data on GHRH + secretagogue combinations.

Frequently Asked Questions

Q: Can I use CJC-1295 with DAC instead of the no-DAC version? The DAC version extends the half-life to 6–8 days, creating a continuous background elevation in GH. Some practitioners prefer non-DAC for pulsatile dosing that more closely mimics natural GH rhythms. Both are used clinically; non-DAC gives more timing control.

Q: Do I need to inject near a muscle or injury site? No. For systemic effects — body composition, anti-aging, sleep — subcutaneous abdominal injection is standard. Site-specific injection is more relevant for peptides like BPC-157 targeting localized injury.

Q: How often should I check IGF-1 levels? Baseline before starting, then at 6 and 12 weeks. Target range for optimization is typically 200–350 ng/mL. If IGF-1 exceeds 400 ng/mL, reduce dose or frequency.

Q: Is PCT (post-cycle therapy) needed? No. Unlike anabolic steroids, GH peptide stacks do not suppress the hypothalamic-pituitary-gonadal axis. Natural GH production returns to baseline within days of stopping. No PCT is required.

Q: Can women use this stack? Yes. Women tend to have higher baseline GH levels than men and often require lower doses. Starting at 100 mcg per injection once daily is a common female protocol. IGF-1 monitoring is equally important.